Proteomics International Laboratories (ASX:PIQ) has appointed Vicki Robinson as an independent non-executive director, strengthening its board as the company advances the commercial roll-out of its lead diagnostic products.
Ms Robinson brings more than two decades of experience in senior executive, legal and commercial management roles, including at Wesfarmers, where she served on the leadership team and as Company Secretary across the group and several subsidiaries between 2020 and 2023.
She holds a Bachelor of Laws (Honours) and Bachelor of Commerce from the University of Western Australia and currently serves on the boards of Perron Group, RACWA Holdings, RAC Finance, Perron Institute of Neurological and Translational Science, and St Ives Group. She is a Fellow of the Governance Institute of Australia and a member of the Australian Institute of Company Directors.
Chairman James Williams welcomed the appointment, noting Ms Robinson’s governance expertise and strategic experience would be valuable as the company accelerates commercialisation. “I am delighted to welcome Vicki to the board of Proteomics International,” Dr Williams said. “Having had the privilege of working with Vicki previously, I am confident she will contribute complementary strategic and decision-making skills, coupled with her outstanding governance expertise, to support the commercial roll-out of our products.”
Ms Robinson said she was joining the board at a pivotal time for the company, with its diagnostic technologies poised for wider deployment. “I am excited to join the Proteomics International Board at a pivotal moment for the company as it implements the commercial roll-out of its lead products and undertakes a critical management transition,” she said. “The Proteomics team have built remarkable diagnostic solutions with the potential to transform management of chronic conditions such as diabetic kidney disease, endometriosis and oesophageal cancer. I look forward to supporting the company in realising the full potential of these innovative tests.”
Proteomics International, based in Perth, focuses on precision diagnostics and bio-analytical services in the field of proteomics, which is the large-scale study of proteins. Its lead products include PromarkerD for diabetic kidney disease, PromarkerEndo for endometriosis and PromarkerEso for oesophageal cancer. These technologies are designed to support earlier diagnosis and improved disease management.
The board appointment comes as the company positions itself to expand commercial partnerships and accelerate its transition into a globally focused precision diagnostics business.